Abbvie | Patient Daily

Abbvie

Press release submission | Jul 24, 2021

DALVANCE® (dalbavancin) Receives FDA Approval to Treat Acute Bacterial Skin and Skin Structure Infections in Pediatric Patients

Press release submission | Aug 15, 2020

ABBVIE: New England Journal of Medicine Publishes Positive Phase 3 Data of Venetoclax Combination in Acute Myeloid Leukemia (AML) Patients

Press release submission | Nov 26, 2018

ABBVIE: Receives US FDA Accelerated Approval for VENCLEXTA® (venetoclax) for Treatment of Newly-Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Press release submission | Oct 26, 2018

ABBVIE: To Assume Full Development and Commercial Control of Cystic Fibrosis Research Program

Press release submission | Sep 23, 2018

ABBVIE: Announces $5 Million Donation to Family Reach to Support Children Battling Cancer and Their Families

Carrie Bradon | Nov 28, 2017

AbbVie to take part in Evercore ISI Biopharma Catalyst conference

Kathy Adams | Nov 15, 2017

AbbVie executive to present at Jefferies London Healthcare Conference

Robert Hadley | Nov 7, 2017

FDA fast-tracking review for AbbVie’s endometriosis drug

Trending

Patient Daily | Sep 17, 2025

Patients Come First spokesperson: Drug ads 'are putting lives at risk by encouraging people to abandon essential treatments'

Patient Daily | Sep 17, 2025

PhRMA’s Senior Director on 340B: 'State and federal investigations have shown 340B is often exploited for profit'

Patient Daily | Sep 19, 2025

ENT specialist on ongoing chronic sinus cases: ‘Some of it could be incomplete surgery’

+ Pharmaceuticals

Patient Daily | Sep 23, 2025

Wall Street Journal editorial board alleges hospitals misuse 340B program